Autonomix Medical, Inc. Technology and Early Proof-of-Concept Study Results to be Featured in Poster Presentation at the World-Leading Course in Interventional Cardiovascular Medicine, EuroPCR

Core Insights - Autonomix Medical, Inc. is set to present its technology and early proof-of-concept study results at EuroPCR 2025, a leading course in interventional cardiovascular medicine [1][4] - The presentation will focus on a catheter-based transvascular RF neural ablation technique aimed at alleviating severe pain associated with pancreatic cancer [2][6] Company Overview - Autonomix Medical, Inc. specializes in innovative medical device technologies targeting diseases of the nervous system, with a first-in-class platform that includes a catheter-based microchip sensing array [5][6] - The company's technology aims to enhance the detection and differentiation of neural signals, potentially enabling transvascular diagnosis and treatment of peripheral nervous system diseases [5][6] Technology Development - The initial focus of the technology is on treating pain, particularly in pancreatic cancer, which is known for causing severe discomfort and lacks effective treatment options [6] - The platform technology has the potential to address a wide range of indications, including cardiology, hypertension, and chronic pain management [6]